Trial Profile
Patient characteristics initiating ocrelizumab (OCR) in a real-world setting
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Oct 2018
Price :
$35
*
At a glance
- Drugs Ocrelizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 30 Oct 2018 New trial record
- 12 Oct 2018 Results evaluating the potential of misclassification using an existing algorithm identifying relapse in insurance claims for multiple sclerosis (MS) patients receiving ocrelizumab presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
- 12 Oct 2018 Results describing patient characteristics from a large insurance claims database presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis